why choose us

First received: July 21, 2026

Clinical Trial: COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Cancer
Immune Checkpoint Inhibitors
COVID-19 Vaccination
Survival

Study Type: OBSERVATIONAL


Official Title: COVICI-SURV: COVID-19 Vaccination Around Immune Checkpoint Inhibitor Initiation and Survival in a Nationwide Cohort of Patients With Cancer

Brief Summary: COVICI-SURV is a nationwide, retrospective observational cohort study using the French national health data system (SNDS) to evaluate whether COVID-19 vaccination, particularly mRNA vaccination, received within 100 days before or after immune checkpoint inhibitor (ICI) initiation is associated with survival among adults with cancer. The cohort includes 95,015 adults initiating anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy between 28 December 2020 and 22 March 2023. Pre-ICI vaccination is analysed using inverse…

Read more